Moberg announces positive results from phase ll study of MOB-015 for treatment of nail fungus

Moberg Pharma AB (OMX:MOB)(STO:MOB) today announced positive interim results from its ongoing phase ll study of MOB-015. After six months of treatment with MOB-015, 40 per cent of the patients were mycologically cured and no safety concerns were identified. MOB-015 is a novel topical formulation of terbinafine for the treatment of nail fungus (onychomycosis).

The purpose of the study is to confirm the product concept of MOB-015 and provide a basis for out-licensing and further clinical development. 25 patients will be treated for twelve months and followed for a total of fifteen months with respect to the endpoints that the FDA and EMA normally accept for nail fungus. The primary endpoint is the proportion of patients with mycological cure, defined as negative culture and negative KOH microscopy. The study is conducted with leading expertise in the field at Sahlgrenska University Hospital in Gothenburg, Sweden. Patient enrollment in the study was completed in May 2013 and the final results are expected second half of 2014.

"These 6-month interim data are clearly promising and indicate very competitive performance of MOB-015", said Kjell Rensfeldt, VP R&D at Moberg Pharma.

"We are excited to announce the interim data for MOB-015. Oral terbinafine is the gold standard for the treatment of nail fungus. If the final data follow the trajectory of the interim results for this novel topical formulation, MOB-015 has the potential to become a major advance in the treatment of nail fungus", said Peter Wolpert, CEO of Moberg Pharma.

The results from the interim analysis are no guarantee that the final results at study completion will be positive.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.